Skip to main content

It began one evening on a paper napkin. No, really.

After the acquisition of endometrial ablation innovator Novacept in 2004, a team of women’s health veterans couldn’t stop envisioning a better, non-hormonal solution for heavy periods. Then, one night in 2008, they found themselves with a paper napkin, a pen, and their growing passion to end AUB.

“We asked ourselves, if we could do it all over again, what would we do differently? What changes would we make? So we sketched out a new and improved device on a napkin, and that night Minerva Surgical was born. Seven years later Minerva ES was approved by the FDA.”

AUB is a serious problem

In the prime of their lives, with significant personal and professional responsibilities, 1 in 3 women shoulder the additional burden of pain, heavy bleeding, fatigue and depression–just some of the symptoms associated with AUB1.

One-third of outpatient visits to the gynecologist are for AUB, and AUB accounts for more than 70% of all gynecologic consults in the perimenopausal and post-menopausal years2. This common condition often results in a hysterectomy due to benign causes if not treated.

Under-treated, under-reported and normalized

“Since launching Minerva ES in 2015, we’ve learned a lot about the impact AUB has on women and their daily lives. Hearing first hand how women suffer with fibroids, polyps and heavy periods moved us to double down.”

“In 2020 we acquired three additional devices for the treatment of AUB, creating a complete, best-in-class intrauterine care kit. Now we can make swift progress toward our goal of providing device-enabled solutions for AUB that are uterus-sparing, minimally invasive, safe and effective.”

“By treating the root causes of AUB, physicians give women the best chance of avoiding a hysterectomy.”

The survey

In an international online survey study of 6,179 women aged 18–55


had either been diagnosed with heavy menstrual bleeding (HMB) or thought their menstruation was heavier than average, a common symptom of AUB2.


of these women believed there were no treatment options available for them2.

Uterine fibroids

are cited as the most common indication for hysterectomy, accounting for approximately one-third of all hysterectomies performed3.

Abnormal uterine bleeding

is the next most common indication, accounting for approximately 16% of hysterectomies, while gynecologic cancers account for less than 8% of all hysterectomies3.


is the second most common surgery performed on reproductive-age women in the U.S., after cesarean section. More than 400,000 hysterectomies are performed in the U.S. each year with nearly 68 percent done for benign conditions that involve abnormal uterine bleeding, uterine fibroids and endometriosis4.

“When someone asks me about what we do here, inevitably they mention a person they know who has suffered because of their period. Every month, all year long, they pay the price in many ways. We can do something about it and provide women with effective alternatives to hysterectomies.”

It takes a team to end AUB

We are in continuous pursuit of excellence: in engineering, in customer support, and out in the field where our team serves as an extension of yours. Meet some of the people who bring years of experience in women’s healthcare to work each day, but it’s their passion for ending AUB that drives Minerva forward.

Management Team & Board of Directors

We’re just getting started

There’s never been a better time to join Minerva Surgical. Learn more about what it’s like to work here, view our open positions and get in touch with us.

Ready to help the women in your community?

3. Stewart EA, Shuster LT, Rocca WA. Reassessing hysterectomy. Minn Med. 2012;95(3):36-39.
4. Plotting the Downward Trend in Traditional Hysterectomy
5. Laughlin-Tommaso SK, et al. Cardiovascular and metabolic morbidity after hysterectomy with ovarian conservation: a cohort study. Menopause. 2018 May;25(5):483-492.